I read the Quarterly, it’s unsurprising if you read all of the ANNs. R&D costs are large, trial start ups have the largest costs with CRO & trial sites in the beginning. Multiple now ongoing with a good cash reserve.
We also have new hires in the USA to facilitate the Professional & Scientific running of the company with an increased US presence.
That ‘Small Capex’ interview with LC was pathetic. Aren’t they owned by ‘Next Incestors’?
Not on LC’s part but an interviewer that couldn’t get his head around anything & maybe shouldn’t be interviewing on complex Immunology/Oncology Biotech stocks with more than 1IP in the pipeline to get your head around, try all of IMU’s it’s hard to keep up! That whole interview was derailed I think & LC managed it graciously. End game, it won’t matter.
- Forums
- ASX - By Stock
- IMU
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-103
-
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.8¢ |
Change
0.004(7.41%) |
Mkt cap ! $422.5M |
Open | High | Low | Value | Volume |
5.5¢ | 5.9¢ | 5.4¢ | $904.1K | 15.95M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
26 | 1773494 | 5.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.8¢ | 1938833 | 23 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
26 | 1773494 | 0.057 |
12 | 1564141 | 0.056 |
19 | 1288706 | 0.055 |
9 | 1346528 | 0.054 |
10 | 571905 | 0.053 |
Price($) | Vol. | No. |
---|---|---|
0.058 | 1938833 | 23 |
0.059 | 2302281 | 20 |
0.060 | 2469422 | 25 |
0.061 | 702398 | 8 |
0.062 | 310239 | 4 |
Last trade - 14.14pm 12/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |